A local Omaha woman was the first to ever receive CAR T-cell therapy as an outpatient. Doctors said it was a success, and she ...

The collaboration will fund early-stage clinical development of SB-4826, CIT’s first-in-class SUMO E1 inhibitor, for patients ...

Follicular lymphoma survivor Troy Anderson credited acupuncture and nutrition guidance with easing treatment side effects and ...

A man from Swindon will be taking part in a 38-mile cycle after successfully undergoing treatment for follicular lymphoma.

Genmab has announced that its phase 3 EPCORE FL-1 trial met both primary endpoints in patients with relapsed or refractory ...

Epcoritamab shows promising results in treating relapsed follicular lymphoma, with FDA priority review for a groundbreaking ...

Epkinly with Rituxan and Revlimid, compared to Rituxan and Revlimid alone, reduced risk of progression or death by 79%.

Bristol Myers' Breyanzi sales surged 125% in Q2 to $344M, fueled by new approvals, strong demand and expanded market reach.

Background: Follicular lymphoma (FL) is an incurable disease in which patients will relapse despite the effectiveness of first-line (1L) rituximab-based chemoimmunotherapy (CIT), indicating the need ...

Strati led a study that evaluated acalabrutinib alone or in combination with rituximab for follicular lymphoma. In treatment-naive patients, the combination led to an ORR of 92% and CR rate of 39%.

Follicular lymphoma is a slow-growing form of non-Hodgkin lymphoma, a type of cancer in which the body makes abnormal B lymphocytes, a type of white blood cell. Relapse is common.

FDA approval for Yescarta in follicular lymphoma makes it the first approved CAR-T treatment for this type of cancer. It also marks Gilead Sciences' third approved indication for a CAR-T cell therapy.